282 related articles for article (PubMed ID: 34638263)
1. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.
Pupa SM; Ligorio F; Cancila V; Franceschini A; Tripodo C; Vernieri C; Castagnoli L
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638263
[TBL] [Abstract][Full Text] [Related]
2. The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
Castagnoli L; Ladomery M; Tagliabue E; Pupa SM
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261614
[TBL] [Abstract][Full Text] [Related]
3. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Castagnoli L; Ghedini GC; Koschorke A; Triulzi T; Dugo M; Gasparini P; Casalini P; Palladini A; Iezzi M; Lamolinara A; Lollini PL; Nanni P; Chiodoni C; Tagliabue E; Pupa SM
Oncogene; 2017 Mar; 36(12):1721-1732. PubMed ID: 27641338
[TBL] [Abstract][Full Text] [Related]
4. HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.
Nami B; Wang Z
Cancers (Basel); 2017 Apr; 9(5):. PubMed ID: 28445439
[TBL] [Abstract][Full Text] [Related]
5. The landscape of d16HER2 splice variant expression across HER2-positive cancers.
Volpi CC; Pietrantonio F; Gloghini A; Fucà G; Giordano S; Corso S; Pruneri G; Antista M; Cremolini C; Fasano E; Saggio S; Faraci S; Di Bartolomeo M; de Braud F; Di Nicola M; Tagliabue E; Pupa SM; Castagnoli L
Sci Rep; 2019 Mar; 9(1):3545. PubMed ID: 30837627
[TBL] [Abstract][Full Text] [Related]
6. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review).
Xu L; Han F; Zhu L; Ding W; Zhang K; Kan C; Hou N; Li Q; Sun X
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866766
[TBL] [Abstract][Full Text] [Related]
7. P95 HER2 fragments and breast cancer outcome.
Tural D; Akar E; Mutlu H; Kilickap S
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells and HER2 positive breast cancer: The story so far.
Shah D; Osipo C
Genes Dis; 2016 Jun; 3(2):114-123. PubMed ID: 30123819
[TBL] [Abstract][Full Text] [Related]
9. Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications.
Ordaz-Ramos A; Tellez-Jimenez O; Vazquez-Santillan K
Front Cell Dev Biol; 2023; 11():1221175. PubMed ID: 37492224
[TBL] [Abstract][Full Text] [Related]
10. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Koschorke A; Faraci S; Giani D; Chiodoni C; Iorio E; Canese R; Colombo MP; Lamolinara A; Iezzi M; Ladomery M; Vernieri C; de Braud F; Di Nicola M; Tagliabue E; Castagnoli L; Pupa SM
Cell Oncol (Dordr); 2019 Dec; 42(6):815-828. PubMed ID: 31376137
[TBL] [Abstract][Full Text] [Related]
11. Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform.
Dorraji E; Borgen E; Segura-Peña D; Rawat P; Smorodina E; Dunn C; Greiff V; Sekulić N; Russnes H; Kyte JA
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230782
[TBL] [Abstract][Full Text] [Related]
12. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
13. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
14. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1.
Shah D; Wyatt D; Baker AT; Simms P; Peiffer DS; Fernandez M; Rakha E; Green A; Filipovic A; Miele L; Osipo C
Clin Cancer Res; 2018 Sep; 24(18):4566-4578. PubMed ID: 29895705
[No Abstract] [Full Text] [Related]
16. Breast cancer stem cells and the challenges of eradication: a review of novel therapies.
Saeg F; Anbalagan M
Stem Cell Investig; 2018; 5():39. PubMed ID: 30498750
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
18. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
[TBL] [Abstract][Full Text] [Related]
19. Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance.
Sridharan S; Howard CM; Tilley AMC; Subramaniyan B; Tiwari AK; Ruch RJ; Raman D
Front Oncol; 2019; 9():1003. PubMed ID: 31681564
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
